Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 201657, 11 pages
http://dx.doi.org/10.1155/2014/201657
Review Article

Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations

1Department of Neurology, A.O.U. Maggiore di Novara, Amedeo Avogadro University, Corso Mazzini 18, 28100 Novara, Italy
2Department of Translational Medicine, Section of Neurology and Interdisciplinary Research Centre of Autoimmune Diseases (IRCAD), Via Solaroli 17, 28100 Novara, Italy
3Department of Translational Medicine, Amedeo Avogadro University, Via Solaroli 17, 28100 Novara, Italy

Received 29 September 2013; Accepted 13 November 2013; Published 14 January 2014

Academic Editor: Umberto Dianzani

Copyright © 2014 Paolo Ripellino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Y. K. Van Den Bergh, R. D. M. Hadden, P. Bouche et al., “European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision,” European Journal of Neurology, vol. 17, no. 3, pp. 356–363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Köller, B. C. Kieseier, S. Jander, and H.-P. Hartung, “Medical progress: chronic inflammatory demyelinating polyneuropathy,” The New England Journal of Medicine, vol. 352, no. 13, pp. 1343–1356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Odaka, N. Yuki, and K. Hirata, “Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome,” Journal of Neurology, vol. 250, no. 8, pp. 913–916, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Chiò, D. Cocito, E. Bottacchi et al., “Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 12, pp. 1349–1353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. C. Hughes, D. Allen, A. Makowska, and N. A. Gregson, “Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 11, no. 1, pp. 30–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Vital, A. Vital, A. Lagueny et al., “Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases,” Ultrastructural Pathology, vol. 24, no. 6, pp. 363–369, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. K. V. Toyka and R. Gold, “The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents,” Neurology, vol. 60, no. 8, pp. S2–S7, 2003. View at Google Scholar · View at Scopus
  8. D. Allen, K. Giannopoulos, I. Gray et al., “Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 10, no. 2, pp. 174–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Kuwabara, K. Ogawara, S. Misawa, M. Mori, and T. Hattori, “Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 72, no. 1, pp. 37–42, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. Å. Mygland, P. Monstad, and C. Vedeler, “Onset and course of chronic inflammatory demyelinating polyneuropathy,” Muscle and Nerve, vol. 31, no. 5, pp. 589–593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Bouchard, C. Lacroix, V. Planté et al., “Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy,” Neurology, vol. 52, no. 3, pp. 498–503, 1999. View at Google Scholar · View at Scopus
  12. C. Kamm and U. K. Zettl, “Autoimmune disorders affecting both the central and peripheral nervous system,” Autoimmunity Reviews, vol. 11, no. 3, pp. 196–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. B. C. Kieseier, H. C. Lehmann, and G. M. Z. Hörste, “Autoimmune diseases of the peripheral nervous system,” Autoimmunity Reviews, vol. 11, no. 3, pp. 191–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. L. J. Chi, W. H. Xu, Z. W. Zhang, H. T. Huang, L. M. Zhang, and J. Zhou, “Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 15, no. 4, pp. 345–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Kiefer, B. C. Kieseier, G. Stoll, and H.-P. Hartung, “The role of macrophages in immune-mediated damage to the peripheral nervous system,” Progress in Neurobiology, vol. 64, no. 2, pp. 109–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. B. C. Kieseier, M. C. Dalakas, and H.-P. Hartung, “Immune mechanisms in chronic inflammatory demyelinating neuropathy,” Neurology, vol. 59, no. 12, pp. S7–S12, 2002. View at Google Scholar · View at Scopus
  17. C. Sommer, S. Koch, M. Lammens, A. Gabreels-Festen, G. Stoll, and K. V. Toyka, “Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP,” Neurology, vol. 65, no. 12, pp. 1924–1929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Comi, M. Osio, M. Ferretti et al., “Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP,” Journal of the Peripheral Nervous System, vol. 14, no. 2, pp. 101–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Comi, “Fas-mediated T-cell apoptosis in chronic inflammatory demyelinating polyneuropathy,” Journal of the Peripheral Nervous System, vol. 16, supplement 1, pp. 45–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Comi, T. Fleetwood, and U. Dianzani, “The role of T cell apoptosis in nervous system autoimmunity,” Autoimmunity Reviews, vol. 12, no. 2, pp. 150–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. M. Zu Hörste, H.-P. Hartung, and B. C. Kieseier, “From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve,” Nature Clinical Practice Neurology, vol. 3, no. 4, pp. 198–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. T. H. Brannagan III, “Current diagnosis of CIDP: the need for biomarkers,” Journal of the Peripheral Nervous System, vol. 16, supplement 1, pp. 3–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Latov, M. Dalakas, J.-M. Vallat, P. Donofrio, H.-P. Hartung, and K. V. Toyka, “Biomarkers in the diagnosis and therapy of CIDP: proceedings of the biomarkers faculty meeting; June 89, 2010, Athens, Greece,” Journal of the Peripheral Nervous System, vol. 16, supplement 1, pp. 1–2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. T. Rotta, A. T. Sussman, W. G. Bradley, D. Ram Ayyar, K. R. Sharma, and R. T. Shebert, “The spectrum of chronic inflammatory demyelinating polyneuropathy,” Journal of the Neurological Sciences, vol. 173, no. 2, pp. 129–139, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Cocito, I. Paolasso, G. Antonini et al., “A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy,” European Journal of Neurology, vol. 17, no. 2, pp. 289–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. H. Austin, “Recurrent polyneuropathies and their corticosteroid treatment: with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone,” Brain, vol. 81, no. 2, pp. 157–192, 1958. View at Publisher · View at Google Scholar · View at Scopus
  27. R. H. Oakley and J. A. Cidlowski, “Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids,” Journal of Biological Chemistry, vol. 286, no. 5, pp. 3177–3184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Gold, H.-P. Hartung, and H. Lassmann, “T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms,” Trends in Neurosciences, vol. 20, no. 9, pp. 399–404, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Flammer and I. Rogatsky, “Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms,” Molecular Endocrinology, vol. 25, no. 7, pp. 1075–1086, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. U. K. Zettl, R. Gold, H.-P. Hartung, and K. V. Toyka, “Apoptotic cell death T-lymphocytes in experimental autoimmune neuritis of the Lewis rat,” Neuroscience Letters, vol. 176, no. 1, pp. 75–79, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. U. K. Zettl, R. Gold, K. V. Toyka, and H.-P. Hartung, “Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat,” Journal of Neuropathology and Experimental Neurology, vol. 54, no. 4, pp. 540–547, 1995. View at Google Scholar · View at Scopus
  32. V. I. Leussink, S. Jung, U. Merschdorf, K. V. Toyka, and R. Gold, “High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes,” Archives of Neurology, vol. 58, no. 1, pp. 91–97, 2001. View at Google Scholar · View at Scopus
  33. E. Charmandari, G. P. Chrousos, T. Ichijo et al., “The human glucocorticoid receptor (hGR) β isoform suppresses the transcriptional activity of hGRα by interfering with formation of active coactivator complexes,” Molecular Endocrinology, vol. 19, no. 1, pp. 52–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. K. L. Gross, N. Z. Lu, and J. A. Cidlowski, “Molecular mechanisms regulating glucocorticoid sensitivity and resistance,” Molecular and Cellular Endocrinology, vol. 300, no. 1-2, pp. 7–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. C. Kam, S. J. Szefler, W. Surs, E. R. Sher, and D. Y. M. Leung, “Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids,” Journal of Immunology, vol. 151, no. 7, pp. 3460–3466, 1993. View at Google Scholar · View at Scopus
  36. J. D. Spahn, D. Y. M. Leung, M. T. S. Chan, S. J. Szefler, and E. W. Gelfand, “Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin,” Journal of Allergy and Clinical Immunology, vol. 103, no. 3, pp. 421–426, 1999. View at Google Scholar · View at Scopus
  37. J. F. Modiano, D. Amran, G. Lack et al., “Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin,” Clinical Immunology and Immunopathology, vol. 83, no. 1, pp. 77–85, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Imbach, V. d'Apuzzo, and A. Hirt, “High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood,” The Lancet, vol. 1, no. 8232, pp. 1228–1230, 1981. View at Google Scholar · View at Scopus
  39. E. W. Gelfand, “Intravenous immune globulin in autoimmune and inflammatory diseases,” The New England Journal of Medicine, vol. 367, no. 21, pp. 2015–2025, 2012. View at Google Scholar
  40. M. D. Kazatchkine and S. V. Kaveri, “Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin,” The New England Journal of Medicine, vol. 345, no. 10, pp. 747–755, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Nimmerjahn and J. V. Ravetch, “Anti-inflammatory actions of intravenous immunoglobulin,” Annual Review of Immunology, vol. 26, pp. 513–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. V.-S. Negi, S. Elluru, S. Sibéril et al., “Intravenous immunoglobulin: an update on the clinical use and mechanisms of action,” Journal of Clinical Immunology, vol. 27, no. 3, pp. 233–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. M. C. Dalakas, “Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies,” Neurology, vol. 59, no. 12, pp. S13–S21, 2002. View at Google Scholar · View at Scopus
  44. M. C. Dalakas, “The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile,” Pharmacology and Therapeutics, vol. 102, no. 3, pp. 177–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Jacob and Y. A. Rajabally, “Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies,” Current Neuropharmacology, vol. 7, no. 4, pp. 337–342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. L. Katz, M. M. Frank, V. D. Miletic, and H. Jiang, “Immunoglobulin in the control of complement action,” Immunologic Research, vol. 22, no. 2-3, pp. 137–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. I. Schwab and F. Nimmerjahn, “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?” Nature Reviews Immunology, vol. 13, pp. 176–189, 2013. View at Google Scholar
  48. F. Nimmerjahn and J. V. Ravetch, “Immunology: divergent immunoglobulin G subclass activity through selective Fc receptor binding,” Science, vol. 310, no. 5753, pp. 1510–1512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Aschermann, A. Lux, A. Baerenwaldt, M. Biburger, and F. Nimmerjahn, “The other side of immunoglobulin G: suppressor of inflammation,” Clinical and Experimental Immunology, vol. 160, no. 2, pp. 161–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Tackenberg, I. Jelčić, A. Baerenwaldt et al., “Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 12, pp. 4788–4792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science, vol. 313, no. 5787, pp. 670–673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Jefferis and J. Lund, “Interaction sites on human IgG-Fc for FcγR: current models,” Immunology Letters, vol. 82, no. 1-2, pp. 57–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch, “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science, vol. 320, no. 5874, pp. 373–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. V. Kaveri, S. Lacroix-Desmazes, and J. Bayry, “The antiinflammatory IgG,” The New England Journal of Medicine, vol. 359, no. 3, pp. 307–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. R. A. Hughes, P. Donofrio, V. Bril et al., “Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial,” The Lancet Neurology, vol. 7, no. 2, pp. 136–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Gutierrez-Roelens and B. R. Lauwerys, “Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies,” Current Molecular Medicine, vol. 8, no. 6, pp. 551–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Gold, M. C. Dalakas, and K. V. Toyka, “Immunotherapy in autoimmune neuromuscular disorders,” The Lancet Neurology, vol. 2, no. 1, pp. 22–32, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. H. C. Lehmann, H.-P. Hartung, G. R. Hetzel, O. Stüve, and B. C. Kieseier, “Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders,” Archives of Neurology, vol. 63, no. 8, pp. 1066–1071, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Cortese and D. R. Cornblath, “Therapeutic plasma exchange in neurology: 2012,” Journal of Clinical Apheresis, vol. 28, pp. 16–19, 2013. View at Google Scholar
  60. H. C. Lehmann and H.-P. Hartung, “Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies,” Journal of Neuroimmunology, vol. 231, no. 1-2, pp. 61–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. J.-M. Vallat, C. Sommer, and L. Magy, “Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition,” The Lancet Neurology, vol. 9, no. 4, pp. 402–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Frauger, J. Grassi, V. Pradel et al., “Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals,” Fundamental and Clinical Pharmacology, vol. 25, no. 6, pp. 753–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. P. McCrone, D. Chisholm, M. Knapp et al., “Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy,” European Journal of Neurology, vol. 10, no. 6, pp. 687–694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Blackhouse, K. Gaebel, F. Xie et al., “Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada,” Cost Effectiveness and Resource Allocation, vol. 8, article 14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Mahdi-Rogers, P. McCrone, and R. A. Hughes, “Economic costs and quality of life in chronic inflammatory neuropathies in southeast England,” European Journal of Neurology, vol. 21, no. 1, pp. 34–39, 2014. View at Publisher · View at Google Scholar
  66. D. Cocito, G. Serra, I. Paolasso, D. A. Barilà, L. Lopiano, and L. Cattel, “Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies,” Journal of the Peripheral Nervous System, vol. 17, pp. 426–428, 2012. View at Google Scholar
  67. L. Donaghy, K. R. Mills, S. J. Boniface et al., “Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, no. 7, pp. 778–783, 1994. View at Google Scholar · View at Scopus
  68. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), “Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force,” Neurology, vol. 41, no. 5, pp. 617–618, 1991. View at Google Scholar
  69. J. C. Van Swieten, P. J. Koudstaal, M. C. Visser, H. J. A. Schouten, and J. Van Gijn, “Interobserver agreement for the assessment of handicap in stroke patients,” Stroke, vol. 19, no. 5, pp. 604–607, 1988. View at Google Scholar · View at Scopus
  70. I. S. J. Merkies, P. I. M. Schmitz, F. G. A. Van der Meché, J. P. A. Samijn, P. A. Van Doorn, and Inflammatory Neuropathy Cause and Treatment (INCAT) group, “Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies,” Journal of Neurology Neurosurgery and Psychiatry, vol. 72, no. 5, pp. 596–601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. I. S. J. Merkies, P. I. M. Schmitz, F. G. A. Van Der Meché, and P. A. Van Doorn, “Comparison between impairment and disability scales in immune-mediated polyneuropathies,” Muscle and Nerve, vol. 28, no. 1, pp. 93–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. I. S. J. Merkies and P. I. M. Schmitz, “Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 8, pp. 970–972, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. S. I. Van Nes, E. K. Vanhoutte, P. A. Van Doorn et al., “Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies,” Neurology, vol. 76, no. 4, pp. 337–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. P. A. Panaite, S. Renaud, R. Kraftsik, A. J. Steck, and T. Kuntzer, “Impairment and disability in 20 CIDP patients according to disease activity status,” Journal of the Peripheral Nervous System, vol. 18, no. 3, pp. 241–246, 2013. View at Google Scholar
  75. K. C. Gorson, I. N. Van Schaik, I. S. J. Merkies et al., “Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice,” Journal of the Peripheral Nervous System, vol. 15, no. 4, pp. 326–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. P. J. Dyck, C. J. Boes, D. Mulder et al., “History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation,” Journal of the Peripheral Nervous System, vol. 10, no. 2, pp. 158–173, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. E. K. Vanhoutte, C. G. Faber, S. I. Van Nes et al., “Modifying the Medical Research Council grading system through Rasch analyses,” Brain, vol. 135, no. 5, pp. 1639–1649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. I. S. Merkies, P. I. Schmitz, F. G. van der Meché, and P. A. van Doorn, “Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group,” Neurology, vol. 54, no. 4, pp. 943–949, 2000. View at Google Scholar
  79. P. J. Dyck, P. C. O'Brien, and K. F. Oviat, “Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment,” Annals of Neurology, vol. 11, no. 2, pp. 136–141, 1982. View at Google Scholar · View at Scopus
  80. K. C. Gorson, G. Allam, and A. H. Ropper, “Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy,” Neurology, vol. 48, no. 2, pp. 321–328, 1997. View at Google Scholar · View at Scopus
  81. R. Hughes, F. MedSci, S. Bensa et al., “Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy,” Annals of Neurology, vol. 50, no. 2, pp. 195–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. I. N. van Schaik, “First-line treatment for CIDP: a new piece of the puzzle,” The Lancet Neurology, vol. 11, pp. 478–479, 2012. View at Google Scholar
  83. F. Eftimov, M. Vermeulen, P. A. van Doorn, E. Brusse, I. N. van Schaik, and PREDICT, “Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment,” Neurology, vol. 78, pp. 1079–1084, 2012. View at Google Scholar
  84. S. A. Muley, P. Kelkar, and G. J. Parry, “Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids,” Archives of Neurology, vol. 65, no. 11, pp. 1460–1464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. I. N. van Schaik, F. Eftimov, P. A. van Doorn et al., “Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial,” The Lancet Neurology, vol. 9, no. 3, pp. 245–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. B. Bromberg and O. Carter, “Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data,” Muscle and Nerve, vol. 30, no. 1, pp. 20–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Nemni, S. Amadio, R. Fazio, G. Galardi, S. Previtali, and G. Comi, “Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, pp. 43–45, 1994. View at Google Scholar · View at Scopus
  88. M. M. Mehndiratta, R. A. Hughes, and P. Agarwal, “Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003906, 2004. View at Google Scholar · View at Scopus
  89. A. F. Hahn, C. F. Bolton, N. Pillay et al., “Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study,” Brain, vol. 119, no. 4, pp. 1055–1066, 1996. View at Google Scholar · View at Scopus
  90. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome, “Appropriate number of plasma exchanges in Guillain-Barré syndrome,” Annals of Neurology, vol. 41, pp. 298–306, 1997. View at Google Scholar
  91. C.-P. Tsai, K.-C. Wang, C.-Y. Liu, W.-Y. Sheng, and T.-C. Lee, “Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin,” Journal of Clinical Neuroscience, vol. 14, no. 7, pp. 625–629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Latov, C. Deng, M. C. Dalakas et al., “Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy,” Archives of Neurology, vol. 67, no. 7, pp. 802–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Vermeulen, P. A. Van Doorn, A. Brand, P. F. W. Strengers, F. G. I. Jennekens, and H. F. M. Busch, “Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study,” Journal of Neurology Neurosurgery and Psychiatry, vol. 56, no. 1, pp. 36–39, 1993. View at Google Scholar · View at Scopus
  94. P. A. Van Doorn, A. Brand, P. F. W. Strengers, J. Meulstee, and M. Vermeulen, “High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study,” Neurology, vol. 40, no. 2, pp. 209–212, 1990. View at Google Scholar · View at Scopus
  95. T. Kubori, T. Mezaki, R. Kaji et al., “The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy,” Brain and Nerve, vol. 51, no. 2, pp. 127–135, 1999. View at Google Scholar · View at Scopus
  96. A. F. Hahn, C. F. Bolton, D. Zochodne, and T. E. Feasby, “Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study,” Brain, vol. 119, no. 4, pp. 1067–1077, 1996. View at Google Scholar · View at Scopus
  97. J. R. Mendell, R. J. Barohn, M. L. Freimer et al., “Randomized controlled trial of mg in untreated chronic inflammatory demyelinating polyradiculoneuropathy,” Neurology, vol. 56, no. 4, pp. 445–449, 2001. View at Google Scholar · View at Scopus
  98. P. J. Dyck, W. J. Litchy, K. M. Kratz et al., “A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy,” Annals of Neurology, vol. 36, no. 6, pp. 838–845, 1994. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Vermeulen, “Intravenous immunoglobulin: a first-line treatment in CIDP?” The Lancet Neurology, vol. 7, no. 2, pp. 115–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Eftimov, J. B. Winer, M. Vermeulen, R. de Haan, and I. N. van Schaik, “Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001797, 2009. View at Google Scholar · View at Scopus
  101. Y. A. Rajabally, H. Seow, and P. Wilson, “Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy,” Journal of the Peripheral Nervous System, vol. 11, no. 4, pp. 325–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Sommer and K. Toyka, “Nerve biopsy in chronic inflammatory neuropathies: in situ biomarkers,” Journal of the Peripheral Nervous System, vol. 16, no. 1, pp. 24–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. M. M. Mehndiratta and R. A. Hughes, “Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD002062, 2002. View at Google Scholar · View at Scopus
  104. P. P. Choudhary and R. A. C. Hughes, “Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin,” Quarterly Journal of Medicine, vol. 88, no. 7, pp. 493–502, 1995. View at Google Scholar · View at Scopus
  105. S. Kuwabara, S. Misawa, M. Mori, N. Tamura, M. Kubota, and T. Hattori, “Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 1, pp. 66–70, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Vucic, K. Black, L. E. Baldassari, P. S. Tick Chong, K. T. Dawson, and D. Cros, “Long-term effects of intravenous immunoglobulin in CIDP,” Clinical Neurophysiology, vol. 118, no. 9, pp. 1980–1984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Querol, R. Rojas-Garcia, C. Casasnovas et al., “Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study,” Muscle Nerve, vol. 48, no. 6, pp. 870–876, 2013. View at Publisher · View at Google Scholar
  108. RMC Trial Group, “Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study,” The Lancet Neurology, vol. 8, pp. 158–164, 2009. View at Google Scholar
  109. D.-H. Lee, R. A. Linker, W. Paulus, C. Schneider-Gold, A. Chan, and R. Gold, “Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy,” Muscle and Nerve, vol. 37, no. 3, pp. 406–409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. D. Cocito, G. Serra, Y. Falcone, and I. Paolasso, “The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin,” Journal of the Peripheral Nervous System, vol. 16, no. 2, pp. 150–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. E. Nobile-Orazio, D. Cocito, S. Jann et al., “Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial,” The Lancet Neurology, vol. 11, pp. 493–502, 2012. View at Google Scholar
  112. M. C. Dalakas, “Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies,” Journal of the Peripheral Nervous System, vol. 17, no. 2, pp. 34–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Kuitwaard and P. A. Van Doorn, “Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy,” Drugs, vol. 69, no. 8, pp. 987–1001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Mahdi-Rogers, A. V. Swan, P. A. van Doorn, and R. A. Hughes, “Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy,” Cochrane Database of Systematic Reviews, vol. 11, Article ID CD003280, 2010. View at Google Scholar · View at Scopus
  115. P. J. Dyck, P. O'Brien, and C. Swanson, “Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy,” Neurology, vol. 35, no. 8, pp. 1173–1176, 1985. View at Google Scholar · View at Scopus
  116. D. Cocito, S. Grimaldi, I. Paolasso et al., “Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis,” European Journal of Neurology, vol. 18, no. 12, pp. 1417–1421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. M. H. Barnett, J. D. Pollard, L. Davies, and J. G. McLeod, “Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy,” Muscle & Nerve, vol. 21, pp. 454–460, 1998. View at Google Scholar
  118. T. Umapathi and R. Hughes, “Mycophenolate in treatment-resistant inflammatory neuropathies,” European Journal of Neurology, vol. 9, no. 6, pp. 683–685, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Benedetti, M. Grandis, L. Nobblo et al., “Mycophenolate mofetil in dysimmune neuropathies: a preliminary study,” Muscle and Nerve, vol. 29, no. 5, pp. 748–749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. K. C. Gorson, A. A. Amato, and A. H. Ropper, “Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy,” Neurology, vol. 63, no. 4, pp. 715–717, 2004. View at Google Scholar · View at Scopus
  121. J. L. Good, M. Chehrenama, R. F. Mayer, and C. Lee Koski, “Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy,” Neurology, vol. 51, no. 6, pp. 1735–1738, 1998. View at Google Scholar · View at Scopus
  122. D. E. Gladstone, A. A. Prestrud, and T. H. Brannagan III, “High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy,” Journal of the Peripheral Nervous System, vol. 10, no. 1, pp. 11–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Pestronk, J. Florence, T. Miller, R. Choksi, M. T. Al-Lozi, and T. D. Levine, “Treatment of IgM antibody associated polyneuropathies using rituximab,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 4, pp. 485–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Renaud, P. Fuhr, M. Gregor et al., “High-dose rituximab and anti-MAG-associated polyneuropathy,” Neurology, vol. 66, no. 5, pp. 742–744, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Benedetti, C. Briani, D. Franciotta et al., “Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 3, pp. 306–308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. J. M. Léger, K. Viala, G. Nicolas et al., “Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy,” Neurology, vol. 80, pp. 2217–2225, 2013. View at Google Scholar
  127. K. C. Gorson, N. Natarajan, A. H. Ropper, and R. Weinstein, “Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial,” Muscle and Nerve, vol. 35, no. 1, pp. 66–69, 2007. View at Publisher · View at Google Scholar · View at Scopus